Sign in

    Raghuram Selvaraju • H.C. Wainwright & Co.

    Raghuram Selvaraju's questions to Abeona Therapeutics Inc (ABEO) leadership

    Raghuram Selvaraju's questions to Abeona Therapeutics Inc (ABEO) leadership • Q1 2025

    Question

    Raghuram Selvaraju of H.C. Wainwright & Co. asked about the plan for scaling commercial manufacturing, the net proceeds from the PRV sale, the expected pro forma cash balance, and the prior treatment history of potential ZEVASKYN patients.

    Answer

    Chief Technical Officer Dr. Brian Kevany detailed the manufacturing ramp-up from 4 patients/month at launch to 10 patients/month by early next year using the existing facility. CEO Dr. Vish Seshadri added that a further expansion for post-2027 capacity is being designed. CFO Joe Vazzano stated the net proceeds from the PRV sale will be approximately $152 million. Chief Commercial Officer Dr. Madhav Vasanthavada noted that the majority of potential patients will have been exposed to prior treatments.

    Ask Fintool Equity Research AI

    Raghuram Selvaraju's questions to Urogen Pharma Ltd (URGN) leadership

    Raghuram Selvaraju's questions to Urogen Pharma Ltd (URGN) leadership • Q4 2024

    Question

    Raghuram Selvaraju from H.C. Wainwright asked for more detail on the UGN-102 reimbursement environment, specifically the difference between the initial miscellaneous J-code and the permanent J-code, and also requested an update on enrollment for the UGN-103 UTOPIA trial.

    Answer

    Chief Commercial Officer David Lin explained that the miscellaneous J-code period involves a longer reimbursement timeline (50-60 days), which is expected to be cut in half upon receiving a permanent J-code in January 2026. President and CEO Liz Barrett added that initial uptake will likely be higher in hospitals. Chief Medical Officer Mark Schoenberg confirmed that enrollment for the UGN-103 UTOPIA trial is expected to complete in 2025, with data anticipated in 2026.

    Ask Fintool Equity Research AI